How disruptive Cuban’s company will be depends on the types of drugs it will sell. It’s unclear at this time whether Cuban’s company will be in direct competition with the established players for a wide range of products, or whether it will focus on ni…
Studies show that influenza and SARS-CoV-2 evolve in similar ways. The question is how similar—and whether that means Covid-19 will be as tough to eliminate as the flu, which continues to kill tens of thousands each year.
The man’s aggressive tumors practically disappeared 4 months after infection with the coronavirus. But was the virus definitely responsible?
Vaccines alone won’t end the pandemic, at least not in an expedited way that minimizes death and morbidity. Until a much larger proportion of the population is vaccinated, there must be a coherent, parallel strategy aimed at mitigation and control.
Biden and Democratic leaders in Congress seem to have made a strategic decision on the Covid-19 relief package; power through, making use of the budget reconciliation legislative tool that would expedite the bill’s passage and only require 51 votes in …
Increased rates of infection and deaths in Manaus, Brazil, despite prior infections affecting 76% of the population, serves as a warning that a new variant may reinfect a population infected with an earlier strain. A similar situation may be occurring …
The Biden administration’s move to ban non-US travelers from South Africa from traveling to the US and extending the ban on travelers from Brazil and parts of Europe is an attempt to limit the spread of new, fast-moving Covid variants. But these effort…
For those looking for inflammatory rhetoric on drug prices or executive orders calling for direct price controls, such actions are unlikely to come from the Biden Administration. Rather, it’s expected that an approach will be adopted that builds on Con…
Now that mass vaccinations underway, population immunity, also known as herd immunity, has re-entered the realm of possibility cast in a much different light. But if we have it, how long will it last?
Novavax and Johnson & Johnson (J&J) have released preliminary efficacy data from their large scale phase 3 trials. Their efficacy estimates present critical insights for the potential immune-resistance of these variants.
